Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis

Cornea

Volumn 31, Issue 12, 2012, Pages 1493-1496

  Hata, Masayuki ^a,b   Nakamura, Takahiro ^a,b,c   Sotozono, Chie ^a,b,c   Kumagai, Kyoko ^a,b   Kinoshita, Shigeru ^c   Kurimoto, Yasuo ^a,b  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

infliximab; peripheral ulcerative keratitis; rheumatoid arthritis; scleritis; uvetis

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETAMETHASONE; CYCLOSPORIN; INFLIXIMAB; LEVOFLOXACIN; METHOTREXATE; PREDNISOLONE; STEROID;

AGED; ANTIVIRAL THERAPY; ARTICLE; ATYPICAL CONTINUOUS KERATITIS; CASE REPORT; DRUG EFFICACY; EYE DISCHARGE; FEMALE; HERPES SIMPLEX KERATITIS; HERPES VIRUS; HUMAN; IMMUNITY; KERATITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCLERITIS; TREATMENT RESPONSE; UVEITIS; VISUAL ACUITY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; KERATITIS; SCLERITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870254665     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31826218c7     Document Type: Article

References (16)

1. Harper SL, Foster CS. The ocular manifestations of rheumatoid disease. Int Ophthalmol Clin. 1998;38:1-19. (Pubitemid 28168568)
2. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102:687-692.
3. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984;91:1253-1263.
4. Jabs DA, Mudun A, Dunn JP, et al. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469-476.
5. Malik R, Culinane AB, Tole DM, et al. Rheumatoid keratolysis: a series of 40 eyes. Eur J Ophthalmol. 2006;16:791-797. (Pubitemid 46178104)
6. Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea. 1995;14:408-417.
7. Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum Dis Clin North Am. 2007;33:835-854. vii. (Pubitemid 350122976)
8. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(suppl 61):S52-S57.
9. Kinoshita S, Ohashi Y, Ohji M, et al. Long-term results of keratoepithelioplasty in Mooren's ulcer. Ophthalmology. 1991;98:438-445.
10. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356. (Pubitemid 38183244)
11. Smith JR, Levinson RD, Holland GN, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45:252-257. (Pubitemid 32952905)
12. McCarthy JM, Dubord PJ, Chalmers A, et al. Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol. 1992;19:1358-1361.
13. Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576-584.
14. Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13:335-351. (Pubitemid 41702757)
15. Jin J, Chang Y, Wei W. Clinical application and evaluation of anti-TNFalpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol Sin. 2010;31:1133-1140.
16. Atchia II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. J Clin Rheumatol. 2006;12:291-293. (Pubitemid 44915328)